在早期乳腺癌中,部分期是过时的吗?
1Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA.
Surgical oncology clinics of North America
|September 15, 2023
概括
在70岁或以上的早期,荷尔蒙阳性,HER2阴性乳腺癌患者中,可以省略哨兵淋巴结活检. 节点状态对于年轻的绝经后妇女的放射治疗决定至关重要.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 乳腺癌研究研究 乳腺癌研究
背景情况:
- 关分期对于早期乳腺癌的治疗至关重要,影响局部控制和辅助治疗决策.
- 结节转移的发病率在不同患者亚组之间有显著差异.
- 临床试验已经研究了在特定的乳腺癌人群中下分期的必要性.
研究的目的:
- 审查早期乳腺癌中结节转移的发生率.
- 评估关分期在局部控制和辅助系统治疗决策中的作用.
- 分析临床试验数据,以分析乳腺癌中股分期的情况.
主要方法:
- 对现有文献和临床试验数据的审查,关于乳腺癌中股分期.
- 对患者人口统计,瘤特征 (cT1-2 N0,HR+/HER2) 和与结节转移相关的年龄 (≥70岁) 的分析.
- 对节点状况对放射治疗和全身治疗建议的影响评估.
主要成果:
- 在临床T1-2 N0,激素受体阳性 (HR+) /HER2-阴性乳腺癌的70岁或以上妇女中,可以安全地省略哨兵淋巴结活检.
- 节点状况仍然是选择年轻的绝经后妇女接受放射治疗的关键因素,这些妇女具有类似的瘤特征.
- 在特定的早期乳腺癌队列中,部分期对于全面的治疗计划至关重要.
结论:
- 省略哨兵淋巴结活检是适合选择早期,HR+/HER2-乳腺癌的老年患者.
- 在更年轻的绝经后妇女中,部分期对于指导辅助治疗,特别是放射治疗至关重要.
- 在早期乳腺癌中,根据患者年龄和瘤生物学,需要个性化的关分期方法.
更多相关视频
06:03Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
Published on: February 6, 2020
6.7K
13:35Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
2.7K
相关概念视频
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...